In Brief: Biotronik
This article was originally published in The Gray Sheet
Executive Summary
Biotronik: Initiates Phylax 06 implantable cardioverter defibrillator clinical trial following FDA approval of an investigational device exemption. The trial, which will also employ the Lake Oswego, Oregon firm's SL-ICD single-pass lead system, will investigate "pectoral implantation utilizing `active housing' technology and a unique `modular therapy concept'" for tachyarrhythmia treatment, Biotronik says...